Biogen, Inc. Hits New 52-Week High at $219.20, Marking Significant Milestone

Biogen, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 219.20 on June 29, 2026. This achievement underscores the stock's notable activity in the market, especially considering its 52-week low of USD 121.05. Despite a one-year performance decline of 4.14%, Biogen's current price reflects a strong position within its industry, where the average price-to-earnings (P/E) ratio stands at 17.00. The company maintains a healthy debt-to-equity ratio of 0.14, indicating a solid financial structure. Additionally, Biogen's return on equity is reported at 10.01%, showcasing its efficiency in generating profits from shareholders' equity. With a market capitalization of USD 31,355 million, Biogen continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry, marking this 52-week high as a noteworthy point in its ongoing performance trajectory.